Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 68
- Registration Number
- NCT00238316
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada
🇨🇦Tom Baker Cancer Centre - Calgary, Calgary, Alberta, Canada
Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT00237133
- Locations
- 🇧🇷
Novartis Investigative Site, Vitoria/ES, Brazil
Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment
- Conditions
- Interventions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT00237198
- Locations
- 🇯🇵
Novartis Investigative Site, Shizuoka, Japan
Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT00237211
- Locations
- 🇯🇵
Novartis Investigative Site, Saitama, Japan
Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT00237224
- Locations
- 🇲🇽
Novartis Investigative Site, Guadalajara, Zacatecas, México DF, Mexico
FRAGRANCE Part A Safety: Study to Find a Genetic Signature of de Novo Resistance to Letrozole
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2015-01-06
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 49
- Registration Number
- NCT00199134
- Locations
- 🇧🇪
Jules Bordet Institute, Brussels, Belgium
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
- Conditions
- Interventions
- Drug: doxorubicin hydrochlorideDrug: cyclophosphamideDrug: paclitaxelBiological: filgrastimDrug: capecitabineDrug: methotrexateDrug: vinorelbine tartrateProcedure: needle biopsyProcedure: therapeutic conventional surgeryOther: immunohistochemistry staining methodBiological: trastuzumabDrug: tamoxifen citrateDrug: letrozoleOther: laboratory biomarker analysis
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 50
- Registration Number
- NCT00194779
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1065
- Registration Number
- NCT00171340
- Locations
- 🇻🇪
Novartis Investigative Site, Caracas, Venezuela
🇹🇭Ratchathew, Khonkaen, Thailand
The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 527
- Registration Number
- NCT00171314
- Locations
- 🇪🇸
Novartis Investigative Site, Valencia, Spain
A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 263
- Registration Number
- NCT00171704
- Locations
- 🇬🇧
Novartis Investigative Site, Sheffield, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.